Key Points at a Glance
- After stopping GLP-1 treatment, its effects on hunger and satiety gradually wear off.
- Many people regain some of the weight they previously lost.
- In the STEP 1 extension, participants regained about two-thirds of their previous weight loss on average.
- Lower energy needs after weight loss can make weight maintenance more challenging.
- Protein intake, physical activity, and strength training can support muscle preservation.
- Nutrition and behavior strategies are best established while treatment is still ongoing.
Medications such as Wegovy®, Ozempic®, or Mounjaro® have changed obesity treatment in recent years. Many people benefit from substantial weight loss and reduced hunger. But one question concerns many patients: What actually happens in the body when GLP-1 medications are stopped?
The short answer: The body does not “forget” how to function. However, it gradually returns toward its previous state.
Why Does Hunger Increase Again After Stopping GLP-1?
GLP-1 receptor agonists mimic the body’s own hormone GLP-1 (glucagon-like peptide-1). This hormone influences, among other things:4
- the feeling of fullness in the brain,
- gastric emptying,
- blood sugar,
- insulin secretion.
While taking the medication, many people feel full sooner and think less about food. After stopping, this effect decreases over days to weeks. This does not mean that anything is “broken.” Rather, the hormonal signals that had reduced hunger are no longer present to the same extent.
In addition, the body responds to the previous weight loss by trying to protect its energy reserves. This is a natural, evolutionarily driven mechanism.
Does Everyone Regain Weight?
Not necessarily. However, studies show that many people regain weight after stopping treatment.
In the well-known STEP 1 extension study, participants regained an average of about two-thirds of the weight they had previously lost within one year after stopping semaglutide. At the same time, some of the previous improvements in blood pressure and metabolic markers moved back toward baseline.1
Importantly, this does not mean that treatment has “failed.” Obesity is now considered a chronic condition. Similar to high blood pressure or asthma, long-term treatment may be necessary.3
What Happens to Metabolism?
Many people worry that their metabolism will be permanently damaged by GLP-1 medications. Based on current knowledge, there is no evidence for this.
However, the body’s energy needs usually decrease with weight loss. Someone who loses 20 kilograms, for example, generally uses less energy in daily life than before. If food intake increases again after stopping treatment, this can further contribute to weight regain.
Muscle mass also plays a role: adequate protein intake and regular strength training can help preserve muscle mass as well as possible during weight loss.
How Can Stopping GLP-1 Be Managed as Well as Possible?
Several measures can make the transition easier:
- long-term dietary changes instead of a short-term diet,
- adequate protein intake,
- regular physical activity and strength training,
- strategies for hunger and emotional eating,
- close medical and nutrition therapy support.
It is especially important to have realistic expectations: GLP-1 medications do not only treat body weight. They also influence the biological regulation of hunger and fullness.
Sustainable Success After Stopping GLP-1
After GLP-1 medications are stopped, the hormonal effects of treatment gradually normalize. Hunger and appetite may increase again, and many people regain weight. This is not a sign of insufficient discipline, but a normal biological response of the body to weight loss and changing hunger and fullness signals.
That makes it even more important to build habits that can be maintained over the long term. Adequate sleep, regular physical activity, a structured eating routine, and healthy ways of managing stress can help support the body’s regulation of hunger and fullness.
At The Body Clinic, nutrition therapy support is therefore included in the program at no additional cost. We help patients develop sustainable and practical changes in nutrition and lifestyle to support the long-term success of treatment as effectively as possible, both during GLP-1 therapy and beyond.
This article provides general information and does not replace individualized medical or nutrition therapy advice. Stopping treatment or changing the dosage should always be discussed with the treating medical team.
Sources
- Wilding JPH et al. (2022): Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564.
- Rubino D et al. (2021): Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA, 325(14), 1414–1425.
- German Obesity Society (DAG), German Diabetes Society (DDG), et al.: S3 Guideline: Prevention and Treatment of Obesity. Version 5.0, October 2024.
- Müller TD et al. (2019): Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72–130.